Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

from the Company's 2013 unaudited financial statements and all 2012 financial information is derived from the Company's 2012 unaudited financial statements, as disclosed in the Company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission.

(2)
Our non-GAAP net loss is presented as management uses this supplemental non-GAAP financial measure to evaluate performance period over period, analyze the underlying trends in our business, and establish operational goals and forecasts that are used in allocating resources. We believe by presenting this additional measurement, we our providing investors with greater transparency to the information used by our management for our financial and operational decision-making, as well as allowing investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

(3)
All September 30, 2013 financial information is derived from the Company's 2013 unaudited financial statements and all June 30, 2013 financial information is derived from the Company's 2013 audited financial statements, as disclosed in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission.

(4)
Non-cash financial expenses are items related to the amortization of the discount on the convertible loan and its related issuance costs, the revaluation of warrants and the issuance of shares as a result of the anti-dilution rights of the Company's March 2011 investors.


'/>"/>
SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
(Date:3/4/2015)... Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the ... China, today announced its financial results for the fourth ... Quarter 2014 Financial Highlights , Total sales ... or 36.8% excluding the impact of foreign currency exchange ... the same quarter of 2013. , Gross profit ...
(Date:3/4/2015)... GSI Group Inc. (NASDAQ: GSIG ) (the ... of precision photonics and motion control components and subsystems ... today reported financial results for the fourth quarter and ... in this press release are GAAP measures from continuing ... of 2014, GSI generated revenue of $94.0 million, an ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9
... human clinical data highlight safety profile of BSI-201 in ... subjects with advanced solid tumors ... a,privately held biopharmaceutical company developing novel cancer therapies,today announced that ... the 2008 American Society of Clinical Oncology annual,meeting in Chicago., ...
... ASCO Showed Acceptable Tolerability Profile, ... Low Incidence of Grade 3 and 4 Neuropathy, ... eribulin mesylate (E7389) demonstrated activity in a,heavily pretreated population ... to results of a multi-center Phase II clinical,trial. The ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 Cook For Your Life ... teaches healthy cooking to people touched by cancer, is ... The program, run by founder Ann Ogden, will be ... Management. The unique partnership will expand the program from ... CFYL in 2007. After going through her own cancer ...
(Date:3/4/2015)... growing influence of movies, television, video games and the internet ... with the increasingly frantic lifestyle of modern parents, it can ... what kids are into these days. It seems that every ... , The same is also true for drugs and alcohol. ... talk about them, are constantly changing. These tips put a ...
(Date:3/4/2015)... 2015 Starting February 2015, Dr. Joseph ... procedures at their new location in Surrey. , In ... and Dr. Gabriel Chu also provide comprehensive ophthalmology services, ... named Fraser Valley Cataract and Laser (FVCL). This state ... College of Physicians and Surgeons of British Columbia. Fraser ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The print ... of The San Francisco Chronicle with a circulation of ... readers. Its digital component is distributed nationally through a ... top news sites and partner outlets. To explore the ... , Milorganite is composed of heat-dried microbes that ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2
... Awards Honor Unsung Heroes of Violence Prevention, ... history,with drug abuse, incarceration, and homelessness inspires her ... families. Orlando Ramos brings the,power of education and ... Billie Weiss conducts pioneering public-health research,that helps community- ...
... Nov. 12 Karen Ignagni, President,and CEO of America,s ... response to the new health care reform proposal,released by ... for health care reform. We commend Senator Baucus for,putting ... health,care challenges facing the nation. We look forward to ...
... The American Society of Plastic Surgical Nurses presented its ... a Rutgers College of Nursing faculty member, and her ... 1. , Rankin, clinical associate professor at The ... New Jersey, and her co-authors, Carrie Carretta, an advanced ...
... runs for Prime Minister or President should have an independent ... doctor on bmj.com today. , Lord David Owen, ... says that millions of people are affected by the decisions ... an obligation to the general public to ensure that their ...
... see doctors far more frequently, study finds , , WEDNESDAY, ... failure have many more doctor visits and take more ... , They based their conclusion on an analysis of ... of the beneficiaries was 70.7 years, while the average ...
... states plus Puerto Rico and District of Columbia get failing ... comes to premature birth rates, the United States rates a ... of Columbia get failing grades. , That,s the sobering conclusion ... Report Card , released Wednesday. Not a single state earned ...
Cached Medicine News:Health News:Three Community Leaders to Receive Foundation's 2008 California Peace Prize 2Health News:Three Community Leaders to Receive Foundation's 2008 California Peace Prize 3Health News:World leaders must be more open about their health 2Health News:Heart Failure Accounts for 37% of Medicare Spending 2Health News:U.S. Gets a 'D' for Preterm Birth Rates 2
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
... gives you the exceptional performance you need at ... illumination, comfort and durability youd expect from headlights ... headlight. It features our thinnest cable and adjusts ... flexibility. Now when you reach for a headlight ...
... Sunnex Celestial Star™ light ... applications. The flexible design ... and positioning. The space-saving ... many facilities including emergency ...
The Next Generation in Single Lamp Technology, Advanced Optics & Reflector Design, Extended Depth of Field, 54" Useable Column of Light, High Intensity, Cool Beam Temperature...
Medicine Products: